{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2025-09-19", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "codes": [ { "uuid": "3d8305f7-a59b-4300-904d-3325a16102bb", "code": "G9XQ9S7T2F", "type": "PRIMARY", "code_system": "FDA UNII" } ], "substance_class": "protein", "references": [ { "uuid": "deb8c6be-f0f8-4250-a88d-5c21f287991f", "citation": "https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine#section=Biological-Test-Results", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine", "doc_type": "PUBCHEM", "public_domain": true, "tags": [ "POT" ] }, { "uuid": "a6c27778-645e-4263-b87e-eea38754294d", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ff2b6933-1324-4bca-b362-61e9b6451f41", "citation": "http://www.uniprot.org/uniprot/P35462", "url": "http://www.uniprot.org/uniprot/P35462", "doc_type": "UNIPROT", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3052df7f-900f-4878-bd71-efc19eeab7cd", "citation": "UNIPROT", "doc_type": "UNIPROT", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "d0e33799-c62e-4dfc-a4df-0d567f734f4c", "citation": "Chiò, Adriano, Letizia Mazzini, and Gabriele Mora. \"Disease-modifying therapies in amyotrophic lateral sclerosis.\" Neuropharmacology 167 (2020): 107986.", "url": "https://www.sciencedirect.com/science/article/pii/S0028390820300526", "doc_type": "JA", "public_domain": true }, { "uuid": "2002ab4a-bd53-4c0d-bea1-1a8af685ee48", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2eae9d86-b9b6-439e-84b6-b4bec07db5df", "citation": "Svenningsson, Per, et al. \"Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial.\" npj Parkinson's Disease 4.1 (2018): 35.", "url": "https://www.nature.com/articles/s41531-018-0071-3", "doc_type": "JA", "public_domain": true }, { "uuid": "8acd4cd6-1bde-4ece-8765-9c556db5a301", "citation": "https://www.drugbank.ca/drugs/DB00714#BE0000581", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "e88b13bd-e163-4d0a-9d46-15bf6dcd46c2", "citation": "Wager, Travis T., et al. \"Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects.\" ACS chemical neuroscience 8.1 (2016): 165-177.", "url": "https://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00297", "doc_type": "JA", "public_domain": true, "tags": [ "NOMEN", "POT", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d42de5b0-4bea-499c-a543-e57ddd7f4001", "citation": "Attkins, Neil, et al. \"Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.\" Xenobiotica 40.11 (2010): 730-742.", "url": "https://www.tandfonline.com/doi/full/10.3109/00498254.2010.514961", "doc_type": "JA", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE", "PHARMACOKINETICS" ] }, { "uuid": "7752144c-7c07-42cc-8895-5494648014d1", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf", "doc_type": "FDA APPROVED DRUG LABEL", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b4de605c-915f-43c8-8d5e-57c2f5d0a27b", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "71a9eb7f-6fd3-450d-beff-495e714878f6", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "31a86c7f-d684-4bf0-8099-2b0da059f83b", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf", "doc_type": "FDA APPROVED DRUG LABEL", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "52b3088d-46c6-4851-9478-a6db214726e7", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf", "doc_type": "FDA APPROVED DRUG LABEL", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ce9482a9-f209-477b-84f7-d48d6134e4bf", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "15dcb230-631c-4248-925c-d6415ae58113", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf", "doc_type": "FDA APPROVED DRUG LABEL", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5b2c48e1-8441-4762-ac51-87be038c800a", "citation": "Feng, Meihua Rose, Joseph Loo, and Jonathan Wright. \"Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling.\" Drug metabolism and disposition 26.10 (1998): 982-988.", "url": "https://dmd.aspetjournals.org/content/dmd/26/10/982.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "cda13951-6b73-401f-a665-cff8fe51c969", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "6be1368a-25f3-4b86-9f84-4d8c3fa59cc6", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8fd88c00-a147-41c0-a0c8-23947e34792f", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE", "NOMEN" ] }, { "uuid": "d1b9a629-aa2d-46c3-bedd-d08340e59597", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "052e9411-aa6b-4410-a00b-a5d63913d7fe", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "63470570-7c35-410c-a494-6cce7ca60931", "citation": "Attkins, N. J., et al. \"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061.\" Xenobiotica 39.7 (2009): 523-533.", "url": "https://www.tandfonline.com/doi/full/10.1080/00498250902893775?casa_token=6gs8Uf1iXpgAAAAA%3A7nf-3ir6pzdZMTWvKuSZj8LMBaBK_ryfqNh8J69PsjHVPhVN2cWX9ZIkNogC5htN4hBmGIpP_kSwiw", "doc_type": "JA", "public_domain": true }, { "uuid": "040ef8d9-6e47-4a2d-a375-40f9d1cdfa18", "citation": "Doot, Robert K., et al. \"Selectivity of probes for PET imaging of dopamine D3 receptors.\" Neuroscience letters 691 (2019): 18-25.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123300/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "35472149-6d3d-4cae-ad0a-2ca9c3216f40", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE", "NOMEN" ] }, { "uuid": "2f05e75b-fb4e-4322-8cef-f592ac6f1ff6", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "0cacf472-7e9b-43d1-98ae-086c22ea4502", "citation": "Doot, Robert K., et al. \"Selectivity of probes for PET imaging of dopamine D3 receptors.\" Neuroscience letters 691 (2019): 18-25.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123300/", "doc_type": "JA", "public_domain": true }, { "uuid": "931a9088-c5c8-4ec0-9710-6ecb44147e51", "citation": "https://jpet.aspetjournals.org/content/early/2021/07/12/jpet.121.000698", "url": "https://jpet.aspetjournals.org/content/early/2021/07/12/jpet.121.000698", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "684387a6-83f5-4faf-989e-c6fcf89cde39", "citation": "Bennacef, Idriss, et al. \"Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.\" Bioorganic & medicinal chemistry letters 19.17 (2009): 5056-5059.", "url": "https://d1wqtxts1xzle7.cloudfront.net/40484581/Dopamine_D-3_receptor_antagonists_The_qu20151129-16879-15j4vf8-libre.pdf?1448836054=&response-content-disposition=inline%3B+filename%3DDopamine_D3_receptor_antagonists_The_que.pdf&Expires=1665613604&Signature=PATlivX~YkEckG3GJV-BTse0jU8dGy-U6c4XZDitmrp~U~LtlHfi7qgRxWa6s8dOZl0Ayc2JA21eIqhlf5RVUOTPPt-2gwLMT7wZXIM9TLaH0AHJUH1oXpKNz1vG~~B0i1ar8dJTMSrT2y~Wq-HbNEEr4dOKPa6hlZfJF0JPG3lzUqyPtZsGd2c3A551vDxSzEdM9z-5XcoihnDPpxiFiqqMbECdMB3dJlZ9wdG-vn0MLKrvX1tqaBBbr23tZEwsjnwtZC4JIkMKuOBqZQgHEjiCTtZqAQRCW85pVgKNM-bOrPZB6hfo5DO4ZDYqhhJI0GyTxa5Lxy8u~hO2I2VkyQ__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b384b89d-2000-4a13-88f4-8795a4eca53c", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5a5d2fab-6e78-455c-8524-95c03ff07ff6", "citation": "Bennacef, Idriss, et al. \"Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.\" Bioorganic & medicinal chemistry letters 19.17 (2009): 5056-5059.", "url": "https://d1wqtxts1xzle7.cloudfront.net/40484581/Dopamine_D-3_receptor_antagonists_The_qu20151129-16879-15j4vf8-libre.pdf?1448836054=&response-content-disposition=inline%3B+filename%3DDopamine_D3_receptor_antagonists_The_que.pdf&Expires=1665613604&Signature=PATlivX~YkEckG3GJV-BTse0jU8dGy-U6c4XZDitmrp~U~LtlHfi7qgRxWa6s8dOZl0Ayc2JA21eIqhlf5RVUOTPPt-2gwLMT7wZXIM9TLaH0AHJUH1oXpKNz1vG~~B0i1ar8dJTMSrT2y~Wq-HbNEEr4dOKPa6hlZfJF0JPG3lzUqyPtZsGd2c3A551vDxSzEdM9z-5XcoihnDPpxiFiqqMbECdMB3dJlZ9wdG-vn0MLKrvX1tqaBBbr23tZEwsjnwtZC4JIkMKuOBqZQgHEjiCTtZqAQRCW85pVgKNM-bOrPZB6hfo5DO4ZDYqhhJI0GyTxa5Lxy8u~hO2I2VkyQ__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "9647ef62-02af-4043-914c-2ce9e7cad778", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7961654a-7168-410a-9cc6-8130c400b018", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5c0d6559-144c-4c92-a9df-a2a25a888505", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4473966c-f7a2-4fe1-b435-622529f7e3f8", "citation": "Shapiro, David A., et al. \"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.\" Neuropsychopharmacology 28.8 (2003): 1400-1411.", "url": "https://www.nature.com/articles/1300203", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f73a7eba-cdfe-40ce-ae7a-7f5be088fcda", "citation": "https://go.drugbank.com/drugs/DB12061", "url": "https://go.drugbank.com/drugs/DB12061", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f0cfcb0f-11d9-44c5-95ff-6835ef36af7b", "citation": "https://drugs.ncats.io/drug/7SNB18Q89D", "url": "https://drugs.ncats.io/drug/7SNB18Q89D", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "429a246f-6e70-427c-b985-6506a1e17a34", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "fce9f5e1-fd1b-4cdc-a03e-cc5d20edb0ff", "citation": "Nichols, David E., et al. \"Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD).\" Journal of Medicinal Chemistry 45.19 (2002): 4344-4349.", "url": "https://pubs.acs.org/doi/pdf/10.1021/jm020153s", "doc_type": "JA", "public_domain": true }, { "uuid": "4269213d-eb50-4465-97a2-c290e824586a", "citation": "https://drugs.ncats.io/drug/419A0R564U", "url": "https://drugs.ncats.io/drug/419A0R564U", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "71a6fb18-e795-4b2c-b025-2f1c116842ad", "citation": "https://go.drugbank.com/drugs/DB09223", "url": "https://go.drugbank.com/drugs/DB09223", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "de3d52c7-a1a1-4b55-9ea1-8cfadcf391d1", "citation": "Bourne, James A. \"SCH 23390: the first selective dopamine D1‐like receptor antagonist.\" CNS drug reviews 7.4 (2001): 399-414.", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2001.tb00207.x?sid=nlm%3Apubmed", "doc_type": "JA", "public_domain": true }, { "uuid": "5ffc24eb-a826-401d-828b-29a2f9e37378", "citation": "Bourne, James A. \"SCH 23390: the first selective dopamine D1‐like receptor antagonist.\" CNS drug reviews 7.4 (2001): 399-414.", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2001.tb00207.x?sid=nlm%3Apubmed", "doc_type": "JA", "public_domain": true }, { "uuid": "93cbf858-0da0-4af1-850b-5d63304b913d", "citation": "Bourne, James A. \"SCH 23390: the first selective dopamine D1‐like receptor antagonist.\" CNS drug reviews 7.4 (2001): 399-414.", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2001.tb00207.x?sid=nlm%3Apubmed", "doc_type": "JA", "public_domain": true }, { "uuid": "ecee770b-503e-410d-ba56-8075aa6a3661", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "044a2f69-48c4-40a8-b819-26ac040d934a", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] } ], "definition_type": "PRIMARY", "definition_level": "COMPLETE", "uuid": "a98f13f0-dc55-4a68-ad39-74c161d27375", "version": "74", "unii": "G9XQ9S7T2F", "relationships": [ { "uuid": "ad80eb6b-4a83-4d93-a367-c5cafa54d09b", "amount": { "uuid": "e3e0feac-1314-4569-8a60-bdc367d578bf", "average": 12, "units": "NANOMOLAR" }, "comments": "Emax 82% Transfected CHO cells", "qualification": "EC50", "type": "AGONIST->TARGET", "references": [ "8acd4cd6-1bde-4ece-8765-9c556db5a301" ], "related_substance": { "uuid": "122d8f7b-153c-4338-a1f5-b7298d3da083", "refuuid": "d5382a9f-4b7e-432d-bf4d-03a5473c8f22", "name": "APOMORPHINE", "unii": "N21FAR7B4S", "linking_id": "N21FAR7B4S", "ref_pname": "APOMORPHINE" } }, { "uuid": "c25bc231-6ef9-40b6-bedf-91588febd96e", "amount": { "uuid": "987a9927-a8bf-44f8-bead-c93f5aecec79" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "189bb8ea-8264-4c9c-a5fa-dda9bc5cb7c6", "refuuid": "a3cbd3a3-7846-4771-b0d0-7c6b4441cf8d", "name": "PERGOLIDE", "unii": "24MJ822NZ9", "linking_id": "24MJ822NZ9", "ref_pname": "PERGOLIDE" } }, { "uuid": "8d703844-6d1a-40ff-ae8d-f96bb480f9de", "amount": { "uuid": "74f0bc95-3bde-4248-8db0-0671d914bfd4" }, "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "92404389-3957-497c-af93-f55cbc234754", "refuuid": "290d9815-8602-4636-ab28-7497ef98895b", "name": "Brilaroxazine", "unii": "X8L60BA01I", "linking_id": "X8L60BA01I", "ref_pname": "Brilaroxazine" } }, { "uuid": "d8f3894e-c852-437e-9045-fc7546771fe3", "amount": { "uuid": "4df514b0-972d-4654-82ed-18bcdcddda47", "average": 3.2, "units": "NANOMOLAR" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "7aad27bb-37db-4418-af94-1f8d18b7a33e", "refuuid": "6fca0332-91d4-44db-b125-81cc3c1639ea", "name": "SB-773812", "unii": "ZNP5SNF9FY", "linking_id": "ZNP5SNF9FY", "ref_pname": "SB-773812" } }, { "uuid": "48ae1463-e033-423f-8d06-489c483f6914", "amount": { "uuid": "0e7b97fe-396d-4bb1-88d2-8472eb70a5e3" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "ba89a03f-bc68-41ee-a245-aea11cf3d434", "refuuid": "b1f67d7b-63e2-4936-916e-9adc6a636638", "name": "GSK-598809", "unii": "Y5OZ63HC3V", "linking_id": "Y5OZ63HC3V", "ref_pname": "GSK-598809" } }, { "uuid": "36802c20-b996-4873-acb2-0c80d31952a6", "amount": { "uuid": "e7c05e19-17a6-46c1-8126-f63c103b59fb", "average": 90, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "2eae9d86-b9b6-439e-84b6-b4bec07db5df" ], "related_substance": { "uuid": "088a7140-6c7c-45c5-9626-9aa42e75431a", "refuuid": "45dab35e-6d69-4b70-bec8-d58b5c11f8dc", "name": "MESDOPETAM", "unii": "HD4QV8GX26", "linking_id": "HD4QV8GX26", "ref_pname": "MESDOPETAM" } }, { "uuid": "ccb2164a-bcc2-4ea7-9cfe-a38b85ad6c75", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "cf9006dc-1f1a-43eb-9d09-8100ccf6178d", "refuuid": "731f67a1-c8e1-47fb-8643-d7f92f761216", "name": "BP-14979", "unii": "XN7HA74WB0", "linking_id": "XN7HA74WB0", "ref_pname": "BP-14979" } }, { "uuid": "afb0b9f2-367f-4c35-aa23-21099bbed736", "type": "AGONIST->TARGET", "related_substance": { "uuid": "351cf606-4a4d-49a4-88bb-a2f2973f0983", "refuuid": "42309f06-bb6c-4965-90ab-debd7c516554", "name": "ROPINIROLE", "unii": "030PYR8953", "linking_id": "030PYR8953", "ref_pname": "ROPINIROLE" } }, { "uuid": "23690cc1-5782-4c13-bf09-edbbe2640ec1", "type": "AGONIST->TARGET", "related_substance": { "uuid": "42bffd00-7a36-434b-9e55-974fbcbe35c5", "refuuid": "23ecdee4-0740-40b6-b006-395ed0d40ac6", "name": "ROTIGOTINE", "unii": "87T4T8BO2E", "linking_id": "87T4T8BO2E", "ref_pname": "ROTIGOTINE" } }, { "uuid": "d4d446dc-7013-45ec-a245-41fc28670432", "type": "AGONIST->TARGET", "related_substance": { "uuid": "d20c9bfc-d455-422e-8b16-4175e6b05d75", "refuuid": "4dae9454-8311-4528-8b18-4d4a3f4e6d32", "name": "PRAMIPEXOLE", "unii": "83619PEU5T", "linking_id": "83619PEU5T", "ref_pname": "PRAMIPEXOLE" } }, { "uuid": "aa9575ff-ae2a-479c-9bbc-2c190aa4c727", "type": "AGONIST->TARGET", "related_substance": { "uuid": "7671e62f-9aea-4a26-abaf-e01e365a137b", "refuuid": "74eb96da-1f5b-4bad-9687-8a221557fb5a", "name": "BROMOCRIPTINE", "unii": "3A64E3G5ZO", "linking_id": "3A64E3G5ZO", "ref_pname": "BROMOCRIPTINE" } }, { "uuid": "35d33252-e95f-418e-a221-1878b8d1fc9c", "amount": { "uuid": "1cdcb7b7-4923-4bd0-8549-fe6614af658d", "average": 0.085, "units": "NANOMOLAR" }, "comments": "Most of the clinically used antipsychotics display fairly high affinity for D3 receptors in vitro, they lack significant D3 receptor binding in vivo. They also do not occupy D3 receptors in schizophrenic patients at clinically-relevant doses, despite having significant and expected D2 receptor occupancy. The lack of in vivo D3 receptor occupancy of currently used antipsychotics may be due to their inability to displace endogenous DA from these sites; especially since DA has approximately 20- fold higher affinity for D3 vs D2 receptors and D3 (but not D2) receptors exist predominantly in a high affinity state for DA”", "qualification": "Ki", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "0680955e-51c1-4d17-9d8f-968fff0f4221", "refuuid": "c2b826fe-75d5-4d80-b36a-3bec1d7c5e24", "name": "CARIPRAZINE", "unii": "F6RJL8B278", "linking_id": "F6RJL8B278", "ref_pname": "CARIPRAZINE" } }, { "uuid": "a60abfbd-8eb0-484d-bddd-1c47dfc207f2", "type": "RADIOLIGAND->TARGET", "related_substance": { "uuid": "6faae831-29b5-4c26-a8ca-4b4c26d32e9e", "refuuid": "f2ef2bf9-0556-48dd-ab49-54a0e5f1692b", "name": "NAXAGOLIDE C-11", "unii": "PJ3R40IQ7L", "linking_id": "PJ3R40IQ7L", "ref_pname": "NAXAGOLIDE C-11" } }, { "uuid": "61472102-d648-4ece-95ad-bf52032e4cce", "amount": { "uuid": "d1c6c108-8818-4132-8170-7a438fca6a4e", "average": 7.1, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "MAJOR", "references": [ "2002ab4a-bd53-4c0d-bea1-1a8af685ee48" ], "related_substance": { "uuid": "776a5fa6-a98b-44ef-a77b-e2d4f3a7e977", "refuuid": "f1476505-8361-4080-8a97-c6b9a0fb89ed", "name": "ILOPERIDONE", "unii": "VPO7KJ050N", "linking_id": "VPO7KJ050N", "ref_pname": "ILOPERIDONE" } }, { "uuid": "ad7a80a6-39e7-417c-b68b-e7125c9eb9ee", "amount": { "uuid": "c129bf1a-5af7-442f-9075-b1d0e7c9a95c", "type": "RELATIVE BINDING AFFINITY", "average": 2.4, "units": "NANOMOLAR", "non_numeric_value": "Dose 400-800mg" }, "qualification": "Ki", "type": "ANTAGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "31a86c7f-d684-4bf0-8099-2b0da059f83b" ], "related_substance": { "uuid": "fad765ab-aeaf-40aa-986e-c7467829642b", "refuuid": "95bb2237-a7ee-4915-9473-84238cba0854", "name": "AMISULPRIDE", "unii": "8110R61I4U", "linking_id": "8110R61I4U", "ref_pname": "AMISULPRIDE" } }, { "uuid": "ea564340-723d-4745-a3bb-8876f20130e1", "type": "AGONIST->TARGET", "references": [ "e88b13bd-e163-4d0a-9d46-15bf6dcd46c2", "d42de5b0-4bea-499c-a543-e57ddd7f4001" ], "related_substance": { "uuid": "c80844ae-874a-4ec4-bcb9-996a199adcae", "refuuid": "563d642b-40d7-4202-9973-8de501e4d108", "name": "PF-592379", "unii": "66B7UY5K7I", "linking_id": "66B7UY5K7I", "ref_pname": "PF-592379" } }, { "uuid": "f5a8262b-c373-4053-b197-65a6c353ea66", "type": "INHIBITOR->TARGET", "references": [ "deb8c6be-f0f8-4250-a88d-5c21f287991f" ], "related_substance": { "uuid": "a717bc73-68bf-42e3-9cc6-ecb6ba9bf8ed", "refuuid": "9f2aa717-4057-41e3-b056-8bc81935a644", "name": "METOPIMAZINE", "unii": "238S75V9AV", "linking_id": "238S75V9AV", "ref_pname": "METOPIMAZINE" } }, { "uuid": "7a0d12c3-972d-4e6c-b25b-abbb508013b8", "type": "AGONIST->TARGET", "interaction_type": "PARTIAL AGONIST", "references": [ "5b2c48e1-8441-4762-ac51-87be038c800a" ], "related_substance": { "uuid": "248a7a95-b224-426d-b07a-8328412f5df2", "refuuid": "6afb11d5-7bc9-4ec9-8969-9fdab4f484bd", "name": "CI-1007", "unii": "Z5XDS9Z25L", "linking_id": "Z5XDS9Z25L", "ref_pname": "CI-1007" } }, { "uuid": "2a142b34-0d22-4bd7-a771-0a9f967bc3a5", "amount": { "uuid": "d9652e57-2b67-4bc9-84cf-bba9c45257ce", "average": 5.5, "high": 7.5, "low": 3.5, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "INHIBITOR ", "references": [ "ce9482a9-f209-477b-84f7-d48d6134e4bf" ], "related_substance": { "uuid": "ec4cb4ce-08f1-40d5-864e-76340b0f6bdd", "refuuid": "d8f372eb-a89e-47ec-a957-bcdb1111df0b", "name": "PALIPERIDONE", "unii": "838F01T721", "linking_id": "838F01T721", "ref_pname": "PALIPERIDONE" } }, { "uuid": "43c17eef-20ef-433c-8531-8f563ce77e21", "amount": { "uuid": "fb4e69ea-7815-4200-9346-f04a12f42e3b", "average": 13, "high": 18, "low": 8, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "WEAK INHIBITOR->TARGET", "interaction_type": "INHIBITOR ", "references": [ "2f05e75b-fb4e-4322-8cef-f592ac6f1ff6" ], "related_substance": { "uuid": "785dd991-3394-41fc-9f44-7ad7d8840105", "refuuid": "95270949-f3d1-440d-8635-faa62495c858", "name": "RISPERIDONE", "unii": "L6UH7ZF8HC", "linking_id": "L6UH7ZF8HC", "ref_pname": "RISPERIDONE" } }, { "uuid": "61007180-15a9-4ce0-a0d7-f48dc078caa7", "amount": { "uuid": "5f9d2553-7f10-4210-9b6e-c52796b79d35" }, "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "429a246f-6e70-427c-b985-6506a1e17a34" ], "related_substance": { "uuid": "8046ae55-fc2c-4d38-853c-8cf73964d27d", "refuuid": "11dfefd8-1b99-41dc-900a-021280e48497", "name": "SB-277011", "unii": "CHW57ND47C", "linking_id": "CHW57ND47C", "ref_pname": "SB-277011" } }, { "uuid": "fe4503a1-0105-4b67-bdf3-08451ce6235b", "amount": { "uuid": "2fb2c187-787e-443a-8c7c-56212c8843dc" }, "type": "AGONIST->TARGET", "references": [ "7961654a-7168-410a-9cc6-8130c400b018" ], "related_substance": { "uuid": "3fbc166d-9148-42a0-aa53-73a824e85d0d", "refuuid": "f51c196c-6cf2-4e95-a3ea-435b44b0bd57", "name": "6-FLUORO-DMT", "unii": "J4CZH8D9EN", "linking_id": "J4CZH8D9EN", "ref_pname": "6-FLUORO-DMT" } }, { "uuid": "9c4cf98c-5da6-410c-bfdc-4a68e3d2cf15", "amount": { "uuid": "cba3f08e-4fc0-42b9-a546-c93b1e38da40" }, "type": "AGONIST->TARGET", "references": [ "052e9411-aa6b-4410-a00b-a5d63913d7fe" ], "related_substance": { "uuid": "ce5b5b69-b40c-489d-ad6c-59d912db08a7", "refuuid": "b714e0ee-d080-4552-924e-a8a46a576f43", "name": "DINOXYLINE", "unii": "9T7B8CV47A", "linking_id": "9T7B8CV47A", "ref_pname": "DINOXYLINE" } }, { "uuid": "9e20aa4d-cd23-46b0-ad9b-ed7a1b4ae873", "amount": { "uuid": "24d3a4e0-edcd-475c-a411-c6214f532db0", "average": 0.17, "units": "NANOMOLAR" }, "comments": " D3-selective radiotracer.", "qualification": "Ki", "type": "RADIOLIGAND->TARGET", "references": [ "040ef8d9-6e47-4a2d-a375-40f9d1cdfa18" ], "related_substance": { "uuid": "e370a7e5-fadf-4ae4-b0ac-5e0ed1be65c9", "refuuid": "a644f0af-6ff8-44e9-af74-b34a7362202a", "name": "FLUORTRIOPRIDE F-18", "unii": "94W3VUC3ZF", "linking_id": "94W3VUC3ZF", "ref_pname": "FLUORTRIOPRIDE F-18", "substance_class": "reference" } }, { "uuid": "b9cf01e8-e625-4ea4-b204-1393be7991fc", "amount": { "uuid": "4898e0e9-1f17-4611-9c7f-7c1f3c0f036a" }, "type": "AGONIST->TARGET", "references": [ "35472149-6d3d-4cae-ad0a-2ca9c3216f40" ], "related_substance": { "uuid": "041415c0-1bd7-4b34-9605-3dc3f39100db", "refuuid": "5af17931-7d74-4f61-948c-8f61e2a8f3b3", "name": "8-OH-PBZI", "unii": "B8GYQ9JV5F", "linking_id": "B8GYQ9JV5F", "ref_pname": "8-OH-PBZI" } }, { "uuid": "68b4eb05-c3ce-4700-8eec-b28134f40576", "amount": { "uuid": "eb829c33-b24c-4be7-8ce3-d840638bcd27" }, "type": "INHIBITOR->TARGET", "references": [ "d0e33799-c62e-4dfc-a4df-0d567f734f4c" ], "related_substance": { "uuid": "9a5e1c7d-a00b-43e9-aef0-0073132e1f96", "refuuid": "853e38c8-ffda-4379-bfb6-e8bf16b17b6a", "name": "PIMOZIDE", "unii": "1HIZ4DL86F", "linking_id": "1HIZ4DL86F", "ref_pname": "PIMOZIDE", "substance_class": "reference" } }, { "uuid": "4bcf61cd-4694-4bf1-825b-5856aa0825ce", "amount": { "uuid": "6982947a-f6cb-40c7-b6b0-c350eb3f8ea6" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "27dfc456-bfe6-442c-88f4-b1840cc87fcc", "refuuid": "9e0859c7-5014-4c51-a734-ffd7fd412a05", "name": "CORYDALMINE, (-)-", "unii": "DV8DX4568D", "linking_id": "DV8DX4568D", "ref_pname": "CORYDALMINE, (-)-" } }, { "uuid": "8d95475a-6daa-4c16-a300-f47649550928", "amount": { "uuid": "d5214917-21cc-4b1b-86b0-35f93a95cb43", "average": 15, "units": "NANOMOLAR" }, "comments": "A potent and highly selective agonist for the dopamine D3 receptor.", "qualification": "EC50", "type": "AGONIST->TARGET", "references": [ "63470570-7c35-410c-a494-6cce7ca60931" ], "related_substance": { "uuid": "73f950d5-5fe2-41a6-bc1d-7ab29586ac55", "refuuid": "25e05feb-2a49-4488-befb-3abb714c1cd2", "name": "PF-219061", "unii": "ZK5ZP8L5S2", "linking_id": "ZK5ZP8L5S2", "ref_pname": "PF-219061" } }, { "uuid": "cee3997d-5d7b-4d05-b620-aa3564f49d8d", "amount": { "uuid": "892592e9-5eaf-4120-8687-5fcdb45e1034", "average": 3.5, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "0cacf472-7e9b-43d1-98ae-086c22ea4502" ], "related_substance": { "uuid": "318c0ca2-c8f6-4e0f-83bf-eb5ce4387b4c", "refuuid": "60bb5373-f75c-4688-bece-689e121085f0", "name": "RACLOPRIDE", "unii": "430K3SOZ7G", "linking_id": "430K3SOZ7G", "ref_pname": "RACLOPRIDE", "substance_class": "reference" } }, { "uuid": "3bba0b37-00ee-442e-9f04-12978f630c02", "amount": { "uuid": "0dd0a394-7e86-4762-89f8-4770f807df6a" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "64243239-3082-415b-b993-148d5e8366cc", "refuuid": "6ee93f49-30dd-4dc0-8a7f-3fa244561391", "name": "3-(2-oxo-3-{2-[4-(trifluoromethyl)piperidin-1-yl]ethyl}imidazolidin-1-yl)benzonitrile", "unii": "8K5G4U34CU", "linking_id": "8K5G4U34CU", "ref_pname": "3-(2-oxo-3-{2-[4-(trifluoromethyl)piperidin-1-yl]ethyl}imidazolidin-1-yl)benzonitrile", "substance_class": "reference" } }, { "uuid": "b5ada9c7-ef1d-49e7-815a-8d354ddd9b5e", "amount": { "uuid": "a242cc88-22ad-4be3-b951-caca8b2f1d17" }, "comments": "Did not image D3 receptors.", "type": "RADIOLIGAND->TARGET", "references": [ "5a5d2fab-6e78-455c-8524-95c03ff07ff6", "9647ef62-02af-4043-914c-2ce9e7cad778" ], "related_substance": { "uuid": "96c5c971-78e6-4aeb-a775-53b24e93256b", "refuuid": "7efd2ba1-a762-47c9-9035-94a18beaa119", "name": "3-[2-Oxo-3-[2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]-1-imidazolidinyl]benzonitrile-cyano-11C", "unii": "C2PJP69BQR", "linking_id": "C2PJP69BQR", "ref_pname": "3-[2-Oxo-3-[2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]-1-imidazolidinyl]benzonitrile-cyano-11C", "substance_class": "reference" } }, { "uuid": "0355dc74-8545-428f-b98e-9cc1201f454c", "amount": { "uuid": "4fb62370-1ee6-4abe-85ee-be0ab38ae274" }, "type": "INHIBITOR->TARGET", "references": [ "931a9088-c5c8-4ec0-9710-6ecb44147e51" ], "related_substance": { "uuid": "7c1cb4db-67b8-42f5-a4e4-15d31893a6e3", "refuuid": "59346899-cf62-4a03-8574-a706654ef917", "name": "TRAZPIROBEN", "unii": "FH87H57Q4Y", "linking_id": "FH87H57Q4Y", "ref_pname": "TRAZPIROBEN", "substance_class": "reference" } }, { "uuid": "e74fa25c-08b1-40f5-93a5-1f9e5dba2e17", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "a6c27778-645e-4263-b87e-eea38754294d" ], "related_substance": { "uuid": "30ccc14a-ae72-412f-b83c-e2cd21821768", "refuuid": "6da14dc0-0741-4dee-bf23-259b32b38404", "name": "DESMETHOXYFALLYPRIDE", "unii": "CJD4EF9EME", "linking_id": "CJD4EF9EME", "ref_pname": "DESMETHOXYFALLYPRIDE" } }, { "uuid": "cdb8d244-ace3-44ac-926c-7393bb010b3a", "amount": { "uuid": "e4ee9393-19a0-4816-b9b9-765a0091cebb" }, "type": "INHIBITOR->TARGET", "references": [ "4269213d-eb50-4465-97a2-c290e824586a" ], "related_substance": { "uuid": "65393ce0-1d33-4a9e-b105-f263a8aa5f09", "refuuid": "458f966c-d4da-4fdb-b056-bcb4d135a15e", "name": "ELOPIPRAZOLE", "unii": "419A0R564U", "linking_id": "419A0R564U", "ref_pname": "ELOPIPRAZOLE", "substance_class": "reference" } }, { "uuid": "427dbfe0-af19-4d0d-8eca-a549f882c61e", "amount": { "uuid": "f809ad52-0880-4ea8-8120-827f98054d2b", "average": 2.3 }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "d2380f73-040f-406a-bf0e-86802c509c23", "refuuid": "44113624-19ec-4631-951f-e3a91606efb8", "name": "BROMPERIDOL", "unii": "LYH6F7I22E", "linking_id": "LYH6F7I22E", "ref_pname": "BROMPERIDOL", "substance_class": "reference" } }, { "uuid": "8218555b-5bc6-479e-94ad-9dbb26f75c33", "amount": { "uuid": "713da550-b9e9-4add-86ff-a326e417dcf4", "average": 27, "high": 33, "low": 21, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "LIGAND->OFF TARGET", "interaction_type": "BINDING", "references": [ "fce9f5e1-fd1b-4cdc-a03e-cc5d20edb0ff" ], "related_substance": { "uuid": "ba3efe73-b28a-4bf7-994d-7a1f395f2129", "refuuid": "47838978-2214-4228-a38b-9ed5b1b283a3", "name": "LYSERGIDE", "unii": "8NA5SWF92O", "linking_id": "8NA5SWF92O", "ref_pname": "LYSERGIDE", "substance_class": "reference" } }, { "uuid": "25213c57-8a68-4e77-b508-9ccd25828a70", "amount": { "uuid": "c5cce43c-bd04-4f01-a9ad-57be9f100d17" }, "type": "INHIBITOR->TARGET", "references": [ "71a6fb18-e795-4b2c-b025-2f1c116842ad" ], "related_substance": { "uuid": "29c77876-e107-414d-8308-68dc69d197cb", "refuuid": "d0fa9211-2b23-4b76-be8f-760f995aaf7f", "name": "BLONANSERIN", "unii": "AQ316B4F8C", "linking_id": "AQ316B4F8C", "ref_pname": "BLONANSERIN", "substance_class": "reference" } }, { "uuid": "9d263c7d-44bc-4089-ae20-e54b9d9fc6fd", "amount": { "uuid": "b55c74af-671f-442d-afc6-af9264a57e45" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "91a26b2d-6bf5-4122-9121-ba443dce85d3", "refuuid": "c8be447d-d74f-4ac5-9f25-a45736d8c5cc", "name": "F-17464 FREE BASE", "unii": "TDB64DDB5X", "linking_id": "TDB64DDB5X", "ref_pname": "F-17464 FREE BASE", "substance_class": "reference" } }, { "uuid": "abb9be71-a012-49a0-bdc9-6f870791c11c", "amount": { "uuid": "485a441d-8170-4fa8-b9cf-c5549c61f22a", "average": 1, "high": 1.4, "low": 0.6, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "PARTIAL AGONIST->TARGET", "references": [ "4473966c-f7a2-4fe1-b435-622529f7e3f8" ], "related_substance": { "uuid": "1e23d681-9cfc-4538-b5e0-3f3530202d38", "refuuid": "c193f733-fa48-4704-bbca-957a3c6dff6c", "name": "ARIPIPRAZOLE", "unii": "82VFR53I78", "linking_id": "82VFR53I78", "ref_pname": "ARIPIPRAZOLE", "substance_class": "reference" } }, { "uuid": "0deaa72a-9d8b-4ec8-a2e6-24e276e6c95d", "amount": { "uuid": "939a8df0-b8ed-4a6a-9872-894d6891c720" }, "type": "INHIBITOR->TARGET", "references": [ "f0cfcb0f-11d9-44c5-95ff-6835ef36af7b" ], "related_substance": { "uuid": "cb52feaa-d51e-4a71-bd94-a34d9f1c8404", "refuuid": "df9ef20c-25d3-4a09-b6f2-c25302bebb60", "name": "ADOPRAZINE", "unii": "7SNB18Q89D", "linking_id": "7SNB18Q89D", "ref_pname": "ADOPRAZINE", "substance_class": "reference" } }, { "uuid": "8642fba6-dcd2-4799-a0b7-ff1261ae246c", "amount": { "uuid": "9f377186-b555-4e2e-bce2-cdb7bef38dd7" }, "type": "RADIOLIGAND->TARGET", "related_substance": { "uuid": "2e791352-4290-4169-999b-ee2c45c1c517", "refuuid": "37736895-d413-4eed-8cea-956919705d3f", "name": "IOLOPRIDE I-123", "unii": "5E76SOQ99K", "linking_id": "5E76SOQ99K", "ref_pname": "IOLOPRIDE I-123", "substance_class": "reference" } }, { "uuid": "28e9104f-e93f-4438-a155-4f6d094553ac", "amount": { "uuid": "a1c9e367-9ed3-4169-824c-1129db24762a" }, "type": "PARTIAL AGONIST->TARGET", "references": [ "f73a7eba-cdfe-40ce-ae7a-7f5be088fcda" ], "related_substance": { "uuid": "f37c556c-3df4-4e7b-a650-004ee94c6469", "refuuid": "fca1e40b-2e85-4ae2-957a-0c470db06eba", "name": "PARDOPRUNOX", "unii": "5R72CHP32S", "linking_id": "5R72CHP32S", "ref_pname": "PARDOPRUNOX", "substance_class": "reference" } }, { "uuid": "2be70344-0d07-4874-9a22-4e267f162406", "amount": { "uuid": "8ea78af0-46ee-4ef9-8f0b-52e475f69d3d" }, "type": "INHIBITOR->TARGET", "references": [ "ecee770b-503e-410d-ba56-8075aa6a3661" ], "related_substance": { "uuid": "5e66087d-e599-4078-9ea2-eaba74d515a2", "refuuid": "a8d38b50-13f5-4a24-9606-9c3aea20eb17", "name": "N-[(3R)-4-[4-(3-Chloro-5-ethyl-2-methoxyphenyl)-1-piperazinyl]-3-hydroxybutyl]-1H-indole-2-carboxamide", "unii": "45L365B7XN", "linking_id": "45L365B7XN", "ref_pname": "N-[(3R)-4-[4-(3-Chloro-5-ethyl-2-methoxyphenyl)-1-piperazinyl]-3-hydroxybutyl]-1H-indole-2-carboxamide", "substance_class": "reference" } }, { "uuid": "1594e016-70b1-4942-9f90-0b13608a499b", "amount": { "uuid": "8cb12964-bc14-4279-ac82-7534dd9801c1", "average": 4, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "AGONIST->TARGET", "references": [ "93cbf858-0da0-4af1-850b-5d63304b913d" ], "related_substance": { "uuid": "86612814-7899-4cd0-b037-b6fe27e56783", "refuuid": "11cfc6b9-4651-4a5c-98b9-284d8fbe2b50", "name": "DOPAMINE", "unii": "VTD58H1Z2X", "linking_id": "VTD58H1Z2X", "ref_pname": "DOPAMINE", "substance_class": "reference" } }, { "uuid": "38e39c2c-ff35-4127-bed6-9bdce97004d0", "amount": { "uuid": "3657b574-2fbc-43a8-84da-14f6c9476e2f", "average": 0.8, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->OFF-TARGET", "references": [ "de3d52c7-a1a1-4b55-9ea1-8cfadcf391d1" ], "related_substance": { "uuid": "f83d6ffc-a67f-4361-8dd9-913605d7bfe2", "refuuid": "13369292-c650-4ac4-be6a-dadb9d87a173", "name": "SCH-23390", "unii": "UGT5535REQ", "linking_id": "UGT5535REQ", "ref_pname": "SCH-23390", "substance_class": "reference" } }, { "uuid": "dcf4d17b-4280-4522-99af-2c7d95c2342e", "amount": { "uuid": "c05ccc6b-8662-40fb-82e7-a1dd76a23d4b", "average": 7, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "5ffc24eb-a826-401d-828b-29a2f9e37378" ], "related_substance": { "uuid": "f462613e-0892-4b6f-825d-d648411775bc", "refuuid": "cb034a38-8a43-4112-9760-cae598710d66", "name": "HALOPERIDOL", "unii": "J6292F8L3D", "linking_id": "J6292F8L3D", "ref_pname": "HALOPERIDOL", "substance_class": "reference" } } ], "names": [ { "uuid": "8c256708-65cb-4e59-a847-adf70e5cd5af", "name": "D(3) DOPAMINE RECEPTOR", "stdName": "D(3) DOPAMINE RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "3052df7f-900f-4878-bd71-efc19eeab7cd", "ff2b6933-1324-4bca-b362-61e9b6451f41" ], "display_name": true }, { "uuid": "e5e59c49-6e37-4f2f-8c31-9caf518039f8", "name": "D3", "stdName": "D3", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "ff2b6933-1324-4bca-b362-61e9b6451f41" ], "display_name": false }, { "uuid": "c4813480-ccb8-4cb5-bc53-d894212cac07", "name": "D3R", "stdName": "D3R", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "3052df7f-900f-4878-bd71-efc19eeab7cd" ], "display_name": false }, { "uuid": "b0d4ed22-1822-a433-0e38-67df5b51292b", "name": "DOPAMINE D3 RECEPTOR", "stdName": "DOPAMINE D3 RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "ff2b6933-1324-4bca-b362-61e9b6451f41" ], "display_name": false } ], "protein": { "uuid": "8bd96abb-2f2b-4253-a3c0-3fbdf13fb232", "glycosylation": { "uuid": "4b537772-fbe0-4d27-a3dc-1586f8d8b92f", "glycosylation_type": "HUMAN", "n_glycosylation_sites": [ { "residue_index": 12, "subunit_index": 1 }, { "residue_index": 19, "subunit_index": 1 }, { "residue_index": 97, "subunit_index": 1 }, { "residue_index": 173, "subunit_index": 1 } ] }, "subunits": [ { "uuid": "8102de92-ecfd-4cf4-bbbf-0b6e3dff9f22", "sequence": "MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC", "subunit_index": 1 } ], "references": [ "ff2b6933-1324-4bca-b362-61e9b6451f41" ], "disulfide_links": [ { "sites": [ { "residue_index": 103, "subunit_index": 1 }, { "residue_index": 181, "subunit_index": 1 } ] }, { "sites": [ { "residue_index": 355, "subunit_index": 1 }, { "residue_index": 358, "subunit_index": 1 } ] } ], "protein_sub_type": "", "protein_type": "RECEPTOR", "sequence_origin": "HUMAN", "sequence_type": "COMPLETE" }, "properties": [ { "uuid": "33835df8-9314-4f4c-b6de-ed4f5a8ccfcc", "name": "MOL_WEIGHT", "type": "amount", "value": { "uuid": "8d9aec52-4fb1-46b8-87f8-f45d00314245", "units": "DA" }, "defining": false, "property_type": "CHEMICAL" }, { "uuid": "282c47c8-dd07-4a99-80f9-f7d4ec84fbdb", "name": "Molecular Formula", "value": { "uuid": "4c3eb3c9-9ff4-426f-95a6-0a8050a42e0c", "type": "ESTIMATED", "non_numeric_value": "C1998H3147N531O552S24" }, "defining": false, "property_type": "CHEMICAL" } ], "modifications": { "uuid": "3bb82ec3-bfed-41bc-a6b7-0b21214ef241" } } ] }